Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UC-101
- Development stage
- Phase 1
- Lead developer
- Chengdu Ucello Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UC-101 is an investigational, allogeneic "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy developed by Chengdu Ucello Biotechnology. It is derived from umbilical cord blood (UCB) and engineered to simultaneously target two key B-cell antigens: CD19 and B-cell maturation antigen (BCMA). This dual-targeting approach is designed to achieve comprehensive depletion of both B cells and long-lived plasma cells, which are central to the autoimmune pathogenesis of systemic lupus erythematosus (SLE). By utilizing umbilical cord blood as a starting material and employing a universal CAR-T (UCAR-T) platform, UC-101 aims to provide a more accessible and standardized treatment option compared to autologous CAR-T therapies, which are often limited by manufacturing timelines and the poor quality of a patient's own T cells. It is currently being evaluated in early-phase clinical trials for patients with refractory systemic lupus erythematosus.
- Other names
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMAUCB-derived CD19/BCMA CAR-T
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on UC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UC-101.